Loading organizations...
Modulim is a technology company.
Modulim develops and commercializes optical imaging solutions leveraging spatial frequency domain imaging (SFDI) for noninvasive tissue and vascular assessment. Its flagship Clarifi® Imaging System, an FDA-cleared device, precisely quantifies and maps five biomarkers related to microvascular tissue oxygenation and perfusion. This advanced technology enables clinicians to identify patients at risk of complications stemming from microvascular dysfunction, particularly in preventing diabetic foot ulcers and amputations.
The company was founded in 2005 by Dr. David Cuccia, who also serves as its Chief Technology Officer, alongside Dr. Amaan Mazhar, Vice President of Research & Development. Their innovative SFDI technology originated from research conducted by Dr. Cuccia and his colleagues at UC Irvine’s Beckman Laser Institute. The founding insight centered on utilizing structured illumination with multiple wavelengths of light to noninvasively assess tissue oxygenation and hemoglobin, deciphering light's interaction within tissue.
Modulim primarily serves clinicians, providing them with critical insights for earlier and more timely intervention in patient care. The company’s overarching vision is to facilitate widespread adoption of its technology to save limbs and lives, improve patient outcomes, and reduce healthcare costs by enabling the early detection and intervention of microvascular complications.
Modulim has raised $11.6M across 3 funding rounds.
Modulim has raised $11.6M in total across 3 funding rounds.
Modulim has raised $11.6M in total across 3 funding rounds.
Modulim's investors include Pangaea Ventures, Fouse, Al Wiegman, Grey Sky Venture Partners, Mitsubishi UFJ Capital, Fresenius Medical Care Ventures, Mitsuharu Miwa, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Cove Fund, Hamamatsu Photonics.
Modulim is a medical‑technology company that develops a non‑contact optical imaging platform (Clarifi) using Spatial Frequency Domain Imaging (SFDI) to measure tissue perfusion and oxygenation at the point of care, with FDA clearance and CE Marking for applications including diabetic foot ulcer risk assessment and wound care management.[2][5]
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
Quick take: Modulim converts academic SFDI research into a practical, regulatory‑cleared point‑of‑care imaging product (Clarifi) that addresses a high‑value unmet need — early, objective detection of compromised tissue perfusion — and is positioned to expand clinical use if it continues to validate outcomes, secure adoption, and integrate with care workflows.[2][5]
Modulim has raised $11.6M across 3 funding rounds. Most recently, it raised $7.0M Series B in January 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2019 | $7.0M Series B | Pangaea Ventures | Fouse, Al Wiegman, Grey Sky Venture Partners, Mitsubishi UFJ Capital |
| Nov 16, 2017 | $4.1M Grant / Series A | Grey Sky Venture Partners | Fresenius Medical Care Ventures, Mitsuharu Miwa, Mitsubishi UFJ Capital, National Institute of Arthritis and Musculoskeletal and Skin Diseases |
| Jul 27, 2016 | $500K Seed | Cove Fund | Hamamatsu Photonics |